Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty SA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation. The press release in this regard is attached.
The above information is a part of company’s filings submitted to BSE.
